By Assoc. Prof. Dr. Mehmet Sorar | Published: 01.07.2025
Parkinson Treatment in Ankara: New Approaches in Treatment
Newer Parkinson’s treatments differ widely in how well they have been tested. Advanced drug and pump therapies and deep brain stimulation (DBS) have randomised trials behind them, while ideas such as adaptive stimulation are at an earlier stage. None has been shown to slow the disease. This page sets out what each approach has shown, where its limits lie and what to ask before choosing one.
Which newer approaches have been tested, and how well?
Each approach below has a different kind of evidence, so the numbers cannot be compared directly. They come from different people, follow-up periods and scales.
| Approach | Evidence | What it showed | Limits |
|---|---|---|---|
| Advanced drug and pump therapies | 2025 review by the International Parkinson and Movement Disorder Society (MDS) of 102 randomised trials in people already taking oral levodopa, each followed for at least 3 months | Extended-release levodopa, several dopamine agonists and other add-on drugs rated efficacious. Continuous intestinal levodopa infusion and continuous subcutaneous apomorphine rated likely efficacious. | Applies to motor fluctuations. The published summary states no safety conclusions. |
| DBS, five-year data | INTREPID 2025, randomised trial against a sham (pretend) procedure, with open-label follow-up to 5 years, meaning everyone knew their treatment | Off-medication motor score improved from 42.8 to 21.1 at year 1 (51%) and to 27.6 at year 5 (36%). | Industry-linked. 137 of 191 implanted people (72%) completed follow-up. Selected participants. |
| DBS earlier in the course of motor complications | EARLYSTIM 2013, randomised trial of 251 people for 2 years | Quality of life score improved by 7.8 points with stimulation and worsened by 0.2 points with medication alone. | Mean age 52, mean disease duration 7.5 years. Serious adverse events in 54.8% versus 44.1%. |
| Focused ultrasound pallidotomy | US Food and Drug Administration (FDA) summary of a sham-controlled trial, 94 people randomised at 19 sites | At 3 months, 68.6% (46 of 67) were responders against 33.3% (8 of 24) with sham. | Three months only, one side of the brain only. 91 of 166 enrolled people entered the main analysis. |
| Directional and adaptive DBS | 2025 narrative review by Leung and colleagues | Directional leads are reported to widen the therapeutic window (the range of settings that help without side effects) by about 40% on average. Early adaptive studies show benefits. | Publication bias, and open problems with biomarkers, battery life and signal artefacts. |
Trial details and the harms reported are in deep brain stimulation in Parkinson’s disease. Adaptive (closed-loop) DBS adjusts stimulation according to brain signals.
Does any new treatment slow Parkinson’s disease?
None has been shown to. The 2018 MDS evidence review covered the highest grade of studies published through 31 December 2016, added 143 new qualifying studies to its earlier edition, and found no clinically useful intervention to prevent or delay progression. For surgery, the benefit it rates is for motor fluctuations and dyskinesia (involuntary jerky movements), not for the course of the disease. The INTREPID authors report that outcomes declined slightly over five years, possibly because of disease progression. A claim that a method halts or reverses Parkinson’s therefore needs strong evidence behind it.
How should you read a study of a new treatment?
A headline such as “improved by a percentage” says little until you know how the study was done. The examples above give a checklist:
- Length of follow-up. The focused ultrasound comparison with sham lasted three months, while INTREPID followed people for five years.
- Who took part. EARLYSTIM enrolled relatively young people early in their motor complications, so its results should not be assumed to apply to older or cognitively impaired patients. INTREPID chose people with more than 5 years of symptoms and at least 33% improvement on levodopa.
- How many were analysed. Only 72% of the implanted INTREPID group completed follow-up, and only 54.8% of the enrolled focused ultrasound participants were available for the main analysis.
- What the control was. A sham procedure and medication alone answer different questions.
- Who paid. INTREPID was industry-linked, with authors from the device maker.
- Whether harms were counted. In EARLYSTIM, serious events related to implantation or the device occurred in 17.7% of the stimulation group.
When should you raise newer options with your doctor?
The 2025 MDS review addresses people who already take oral levodopa and have motor fluctuations, meaning the effect of medicine wears off at times. It places surgery as one option beside advanced drug therapies for that problem. If wearing-off or more frequent off periods affect your day, those are reasons to ask the doctor who manages your medicines which of these options could apply. Which one suits you depends on examination. Do not start, stop or change a treatment without discussing it first.
If you have had a brain procedure of any kind, a seizure, sudden weakness or sudden trouble speaking needs emergency services (112 in Türkiye), not a routine appointment.
What should you ask about a new approach offered in Ankara?
This page does not evaluate any centre in Ankara. If a doctor or centre proposes a newer method, the same questions apply anywhere:
- Which regulator approved this method for Parkinson’s, and for which use? If there is no approval, is that stated openly? For example, the focused ultrasound approval in the FDA summary covers one-sided pallidotomy in adults aged 30 or older with advanced disease.
- Was the supporting study randomised and controlled, how many people did it include and for how long?
- Did the participants resemble you in age, disease duration and response to levodopa?
- Were harms reported in numbers, and which risks apply to you?
- Is the method offered instead of standard treatment or in addition to it?
More questions are in questions to ask about Parkinson’s treatment, and the options before an operation are covered in Parkinson’s surgery options and referral. Magnetic stimulation is discussed in Parkinson and TMS treatment, and the basics of the condition in what Parkinson’s disease is.
Sources
- MDS evidence-based medicine review: treatments for Parkinson’s disease motor fluctuations (2025)
- MDS evidence-based medicine review: treatments for the motor symptoms of Parkinson’s disease (2018)
- INTREPID: Five-year outcomes of subthalamic DBS for Parkinson disease (JAMA Neurology, 2025)
- EARLYSTIM: Neurostimulation for Parkinson’s disease with early motor complications (NEJM, 2013)
- FDA: Summary of safety and effectiveness data, focused ultrasound for Parkinson’s pallidotomy (2021)
- Leung and colleagues: Local field potentials in DBS programming for Parkinson’s disease, a review (2025)
This article is for general information and does not replace medical diagnosis or treatment. Please consult your physician for advice about your own condition.
Assoc. Prof. Dr. Mehmet Sorar
Neurosurgeon in Ankara. Graduated from Gazi University Faculty of Medicine in 1997, specialist since 2004, associate professor since 2019. Full CV
Related treatment page: Parkinson